At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 195 enrolled
Drug / intervention
CIN-107 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease
In Brief
A Phase 2 clinical trial evaluating CIN-107 and Placebo for Uncontrolled Hypertension and Chronic Kidney Diseases. Completed, enrolled 195 participants across 71 sites.
Detailed Summary
This study will evaluate the efficacy and safety of CIN-107 for the treatment of hypertension in patients with uncontrolled hypertension (uHTN) and Chronic Kidney Disease (CKD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUncontrolled Hypertension, Chronic Kidney Diseases
CountriesUnited States
CollaboratorsParexel
Timeline
Phase 2CompletedFinished
2023202420252026
Enrollment StartApr 2022
First PostedJun 2022
Primary CompletionMay 2024
TodayJul 2026
First PostedJun 27, 2022
Enrollment StartApr 29, 2022
Primary CompletionMay 2, 2024
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 4.0 years ago
Interventions
CIN-107drug
Patients will take CIN-107 tablets by mouth once daily.
Placebodrug
Patients will take placebo tablets by mouth once daily.